A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Duke Medical Center, Memorial Sloan Kettering Cancer Center, Medical University of Vienna, Johns Hopkins University, Johns Hopkins Hospital, University of California, San Francisco, University of California, Los Angeles, Bristol-Myers Squibb (United States), University Hospital Zurich, Harvard University, Dana-Farber Cancer Institute
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2508076331